SCHEMBL14224797

SCHEMBL14224797

Cc1cc(-c2nc3ccccc3[nH]2)n(C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 11/20 0.63
KDM4E B2RXH2 9/20 0.63
NPSR1 Q6W5P4 4/20 0.63
RECQL P46063 1/20 0.63
RAB9A P51151 10/20 0.55
SMN1; SMN2 Q16637 10/20 0.55
ALDH1A1 P00352 9/20 0.55
HSD17B10 Q99714 6/20 0.55
PKM P14618 4/20 0.55
TP53 P04637 3/20 0.55
ABCB11 O95342 1/20 0.55
HPGD P15428 8/20 0.54
MAPT P10636 5/20 0.54
HTT P42858 2/20 0.54
LMNA P02545 2/20 0.54
TSHR P16473 1/20 0.54
EPHX2 P34913 1/20 0.52
NFKB1 P19838 2/20 0.49
NFKB2 Q00653 2/20 0.49
RELA Q04206 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14224532 0.85 NPC1 (0.60) NPC1KDM4ENPSR1RECQLRAB9A
SCHEMBL14224796 0.81 AURKA (0.48) NPC1KDM4ENPSR1RECQLRAB9A
SCHEMBL14224799 0.78 KDM4E (0.38) NPC1KDM4ENPSR1RECQLRAB9A
SCHEMBL2293308 0.78 KDM4E (1.00) NPC1KDM4ENPSR1RECQLRAB9A
SCHEMBL16404989 0.77 NPC1 (0.62) NPC1KDM4ENPSR1RECQLRAB9A
SCHEMBL23745062 0.76 RAB9A (0.51) RAB9AMAPTMEN1KMT2APOLB
SCHEMBL3336160 0.75 NPC1 (0.63) NPC1KDM4ENPSR1RECQLRAB9A
SCHEMBL19753886 0.74 NPC1 (0.54) NPC1KDM4ENPSR1RECQLRAB9A
SCHEMBL24630455 0.74 RAB9A (0.56) NPC1KDM4ERECQLRAB9ASMN1; SMN2
SCHEMBL15786288 0.73 SMN1; SMN2 (0.65) NPC1KDM4ENPSR1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090816-A1 ANTI-INFECTIVE BIARYL COMPOUNDS GENESOFT PHARMACEUTICALS, INC. (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090816-A1 ANTI-INFECTIVE BIARYL COMPOUNDS QTRT1, Q6ZSR9, QTRT2 NPC1 796/4885KDM4E 3096/4885NPSR1 2494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.